1. An introduction to propensity score methods for reducing the effects of confounding in observational studies;Austin;Multivar. Behav. Res.,2011
2. Calabresi P.A., Goodin D.S., Jeffery D., et al., 2012. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing–remitting multiple sclerosis.
3. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;New Engl. J. Med.,2010
4. Cohn S., Bermel R.A., Hara-Cleaver C., et al., 2014. Comparative tolerability and efficacy of dimethyl fumarate and fingolimod in multiple sclerosis. In: European Committee for Treatment and Research in Multiple Sclerosis, Boston, MA, 10–13 June.
5. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group;D'Agostino;Stat. Med.,1998